MedDataX Logo

Assessment of Compliance With Antihypertensive Telmisartan Therapy

NCT ID: NCT00470886

Last Updated: 2012-11-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-04-30

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to asses the efficacy and safety of Telmisartan depending on the use of an electronic therapy monitoring device (HelpingHand) in a real life setting and to asses patients compliance to the therapy with Telmisartan in relation to use of electronic therapy monitoring device.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Telmisartan (Kinzal/Pritor, BAY68-9291)

Intervention Type DRUG

Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan (Kinzal/Pritor, BAY68-9291)

Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age over 18
* Untreated or ineffectively treated arterial hypertension

Exclusion Criteria

* Cholestatic disorders and severe hepatic failure
* Allergy to Telmisartan
* Pregnancy and lactation period
* Unwillingness to participate in the study
* Inability to use the drug reminder device
* Unwillingness to use the drug reminder device
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bang & Olufsen Medicom

INDUSTRY

Sponsor Role collaborator

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bayer Sp. z o.o.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Many Locations, , Poland

Site Status

Many Locations, , Slovakia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland Slovakia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KL0710PL

Identifier Type: OTHER

Identifier Source: secondary_id

14237 - KL0710SK

Identifier Type: OTHER

Identifier Source: secondary_id

12827

Identifier Type: -

Identifier Source: org_study_id

NCT00458692

Identifier Type: -

Identifier Source: nct_alias